Clinical Trial Update: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

View source ↗

Summary

Amgen's expanded access protocol for carfilzomib in relapsed and refractory multiple myeloma has been updated, with the drug noted as approved for marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Kyprolis (carfilzomib)

Snippet

Sponsor: Amgen | Conditions: Multiple Myeloma | Status: APPROVED_FOR_MARKETING